Skip to main content

Tropic Biosciences closes oversubscribed $105M Series C for gene-edited crops

Corteva and Forbion co-lead Tropic Biosciences' $105M Series C to scale gene-edited bananas and rice towards commercial production.

Tropic Biosciences closes oversubscribed $105M Series C for gene-edited crops

Tropic Biosciences, a UK gene-editing company, has closed an oversubscribed $105 million Series C round to scale commercial production of its gene-edited tropical crops.

The round was co-led by Corteva, through its Corteva Catalyst platform, and Forbion, through its Planetary Health Bioeconomy Fund, with participation from Temasek, IQ Capital, Just Climate, ABN Amro, Invest International and others.

The Norwich-based company will use the capital to expand large-scale plant production, strengthen global supply chains, and advance its pipeline of disease-resistant banana varieties and its rice portfolio, built on its proprietary GEiGS platform.

The raise is one of the largest European AgTech rounds of early 2026 and signals continued investor appetite for science-led, revenue-stage crop biotechnology.

Source: Bloomberg